open access

Vol 2, No 1 (2011)
Review paper
Published online: 2011-03-24
Get Citation

The perspectives of the targeted therapy in acute myeloid leukemia

Sebastian Grosicki
Hematologia 2011;2(1):23-32.

open access

Vol 2, No 1 (2011)
REVIEW ARTICLES
Published online: 2011-03-24

Abstract

Results of therapy of acute myeloid leukemia (AML) patients are still unsatisfactory. Since the progress in conventional chemotherapeutics is likely approaching its limits, novel targeted therapies are attractive candidates to improve treatment results. In principle, these drugs must target the critical pathogenetic pathway in the disease. Owing to the large heterogeneity of the disease, it is particularly difficult to identify such universal pathogenetic mechanism in AML. However, in recent years we have witnessed rapid progress in molecular diagnostics, characterization of molecular pathways, signaling cascades and epigenetic changes that shape liczthe leukemic phenotypes and facilitate individualized risk assessment and individualized therapeutic strategy. These studies also characterized certain genetic lesions, whose protein products are targetable. The model example of the effective, targeted treatment in AML is the use of the all-trans retinoid acid in acute promyelocytic leukemia with t(15;17)/PML-RARA. The promising results of studies addressing the role of targeted drugs in the individual subtypes of AML raise hope that these approach will find its place in the clinical practice and improve the results of treatment in AML patients.
Hematologia 2011; 2, 1: 23–32

Abstract

Results of therapy of acute myeloid leukemia (AML) patients are still unsatisfactory. Since the progress in conventional chemotherapeutics is likely approaching its limits, novel targeted therapies are attractive candidates to improve treatment results. In principle, these drugs must target the critical pathogenetic pathway in the disease. Owing to the large heterogeneity of the disease, it is particularly difficult to identify such universal pathogenetic mechanism in AML. However, in recent years we have witnessed rapid progress in molecular diagnostics, characterization of molecular pathways, signaling cascades and epigenetic changes that shape liczthe leukemic phenotypes and facilitate individualized risk assessment and individualized therapeutic strategy. These studies also characterized certain genetic lesions, whose protein products are targetable. The model example of the effective, targeted treatment in AML is the use of the all-trans retinoid acid in acute promyelocytic leukemia with t(15;17)/PML-RARA. The promising results of studies addressing the role of targeted drugs in the individual subtypes of AML raise hope that these approach will find its place in the clinical practice and improve the results of treatment in AML patients.
Hematologia 2011; 2, 1: 23–32
Get Citation

Keywords

acute myeloid leukemia; targeted therapy; prognostic factors; chemotherapy

About this article
Title

The perspectives of the targeted therapy in acute myeloid leukemia

Journal

Hematology in Clinical Practice

Issue

Vol 2, No 1 (2011)

Article type

Review paper

Pages

23-32

Published online

2011-03-24

Bibliographic record

Hematologia 2011;2(1):23-32.

Keywords

acute myeloid leukemia
targeted therapy
prognostic factors
chemotherapy

Authors

Sebastian Grosicki

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.